Chen AY, Jemal A, Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009, 115 (16): 3801-3807. 10.1002/cncr.24416.
Article
PubMed
Google Scholar
Davis L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006, 295: 2164-2167. 10.1001/jama.295.18.2164.
Article
Google Scholar
Aschebrook-Kilfoy B, Schechter RB, Shih YC, Kaplan EL, Chiu BC, Angelos P, Grogan R: The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013, Epub ahead of print
Google Scholar
Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008, 21: S37-S43.
Article
PubMed
CAS
PubMed Central
Google Scholar
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003, 95 (8): 625-627. 10.1093/jnci/95.8.625.
Article
PubMed
CAS
Google Scholar
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63: 1454-
PubMed
CAS
Google Scholar
Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinoho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003, 22: 4578-4580. 10.1038/sj.onc.1206706.
Article
PubMed
CAS
Google Scholar
Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005, 12 (2): 245-262. 10.1677/erc.1.0978.
Article
PubMed
CAS
Google Scholar
Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P: The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69 (21): 8317-8325. 10.1158/0008-5472.CAN-09-1248.
Article
PubMed
CAS
Google Scholar
Li C, Lee KC, Schneider EB, Zeiger MA: BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012, 97 (12): 4559-4570. 10.1210/jc.2012-2104.
Article
PubMed
CAS
PubMed Central
Google Scholar
Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M: A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal Clin Endocrinol Metab. 2012, 6 (7): 2333-2340.
Article
Google Scholar
Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O’Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013, 309 (14): 1493-1501. 10.1001/jama.2013.3190.
Article
PubMed
CAS
PubMed Central
Google Scholar
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehamnn B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA: Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007, 1773 (8): 1263-1284. 10.1016/j.bbamcr.2006.10.001.
Article
PubMed
CAS
PubMed Central
Google Scholar
Garnett MJ, Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer cell. 2004, 6 (4): 313-319. 10.1016/j.ccr.2004.09.022.
Article
PubMed
CAS
Google Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038/nature00766.
Article
PubMed
CAS
Google Scholar
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine. 2010, 363: 809-819. 10.1056/NEJMoa1002011.
Article
PubMed
CAS
PubMed Central
Google Scholar
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364: 2507-2516. 10.1056/NEJMoa1103782.
Article
PubMed
CAS
PubMed Central
Google Scholar
Kim K, Cabanillas M, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI: Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600E BRAF mutation. Thyroid. 2013, Epub ahead of print
Google Scholar
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004, 116: 855-867. 10.1016/S0092-8674(04)00215-6.
Article
PubMed
CAS
Google Scholar
Polikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature. 2010, 464 (7287): 427-440. 10.1038/nature08902.
Article
Google Scholar
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S: Raf inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010, 464 (7287): 431-435. 10.1038/nature08833.
Article
PubMed
CAS
Google Scholar
Darzynkiewicz Z, Bedner E, Gorczyca W, Melamed MR: Laser scanning cytometry: a new instrumentation with many applications. Exp Cell Res. 1999, 249: 1-12. 10.1006/excr.1999.4477.
Article
PubMed
CAS
Google Scholar
Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK: Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010, 20: 33-41. 10.1089/thy.2009.0296.
Article
PubMed
CAS
PubMed Central
Google Scholar
Rajoria S, Suriano R, Wilson YL, Schantz SP, Moscatello A, Geliebter J, Tiwari RK: 3,3′-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol Rep. 2011, 25: 491-497.
PubMed
CAS
Google Scholar
Darzynkiewicz Z, Zhao H, Halicka HD, Li J: Cytometry of DNA replication and RNA synthesis: Historical perspective and recent advances based on ‘click chemistry. Cytometry A. 2011, 79A: 328-337. 10.1002/cyto.a.21048.
Article
CAS
Google Scholar
Bianco R, Melisi D, Ciardiello F, Tortora G: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer. 2006, 42 (3): 290-294. 10.1016/j.ejca.2005.07.034.
Article
PubMed
CAS
Google Scholar
Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009, 9: 28-39. 10.1038/nrc2559.
Article
PubMed
Google Scholar
Levitzki A, Klein S: Signal transduction therapy of cancer. Mol Aspects Med. 2010, 31 (4): 287-329. 10.1016/j.mam.2010.04.001.
Article
PubMed
CAS
Google Scholar
Curry JL, Falchook GS, Torres-Cabala C, Tetzlaff MT, Prieto VG: Resistant mechanisms to BRAF inhibitor PLX3032 in melanoma. Expert Rev Dermatol. 2011, 6 (4): 355-357. 10.1586/edm.11.38.
Article
CAS
Google Scholar
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010, 468 (7326): 973-977. 10.1038/nature09626.
Article
PubMed
CAS
PubMed Central
Google Scholar
Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G: Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010, 95 (1): 450-455. 10.1210/jc.2009-0373.
Article
PubMed
CAS
Google Scholar
Xing J, Liu R, Xing M, Trink B: The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032(RG7204). Biochem Biophys Res Commun. 2011, 28: 958-962.
Article
Google Scholar
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012, 11: 873-886. 10.1038/nrd3847.
Article
PubMed
CAS
Google Scholar
Sharma SV, Settleman J: Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21 (24): 3214-3231. 10.1101/gad.1609907.
Article
PubMed
CAS
Google Scholar
Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M: PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigm Cell Melanoma R. 2010, 2: 190-200.
Article
Google Scholar
Liu R, Liu D, Xing M: The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab. 2012, 97 (2): E173-E182. 10.1210/jc.2011-1054.
Article
PubMed
CAS
PubMed Central
Google Scholar
Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhbitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3 (5): 520-533. 10.1158/2159-8290.CD-12-0531.
Article
PubMed
CAS
PubMed Central
Google Scholar